Rising Pharmaceuticals announced the U.S. launch & commercial shipment of a generic version of Lyrica®, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg. Pregabalin Capsules had U.S. sales of approximately $5,497 million for the 12 months ending March 2019, according to IMS Health.
Pregabalin Capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, for adjunctive therapy for the treatment of partial onset seizures in patients 4 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury. The product should be taken only as prescribed.
“The commercialization of Pregabalin Capsules is one of the largest volume launches for the company this year and will provide a cost effective treatment option for people living with debilitating neuropathic pain conditions,” said Vimal Kavuru, Chief Executive Officer for Rising Pharmaceuticals.
Rising Pharmaceuticals, as the exclusive distributor for its development and manufacturing partner, Laurus Labs Limited, who recently received final approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA), will launch the product immediately.